ライフサイエンスコーパス: motor complication

1 therapy alone for patients with PD and early motor complications.

2 control of advanced Parkinson's disease with motor complications.

3 ith the development of potentially disabling motor complications.

4 be initiated first to avoid levodopa-related motor complications.

5 n's disease who have severe levodopa-induced motor complications.

6 patients with Parkinson's disease and early motor complications.

7 o delay the appearance and the extent of the motor complications.

8 in delaying the appearance and the extent of motor complications.

9 n stimulation becomes necessary to alleviate motor complications.

10 ease and to play a role in the occurrence of motor complications.

11 for the use of levodopa is the emergence of motor complications.

12 ns and surgeons who are able to handle these motor complications.

13 n of a dopaminergic drug reduces the risk of motor complications.

14 patterns in basal ganglia neurons leading to motor complications.

15 a that provides clinical benefits but avoids motor complications.

16 will prevent pulsatile stimulation and avoid motor complications.

17 n of dopamine receptors with reduced risk of motor complications.

18 effective treatment for the disease without motor complications.

19 everse motor deficits and reduce the risk of motor complications.

20 trategies that reduce the risk of developing motor complications.

21 nger patients who have a higher incidence of motor complications.

22 vor the appearance of parkinsonian signs and motor complications.

23 future scope for longitudinal monitoring of motor complications.

24 alanine (L-DOPA)-induced dyskinesia (LID), a motor complication affecting Parkinson's disease patient

25 llness, chronic treatment is associated with motor complications and development of features that do

26 ith idiopathic PD who developed uncontrolled motor complications and did not have dementia were rando

27 mergence of increasingly severe drug-induced motor complications and harmful behavioural consequences

28 rategies to delay and treat levodopa-related motor complications and nonmotor Parkinson's disease-rel

29 attempt to reduce or delay the appearance of motor complications and other adverse events.

30 arkinson disease, illustrates these emerging motor complications and the manner in which they may be

31 apies; however, long-term treatment leads to motor complications and, occasionally, impulse control d

32 s in PD-activities of daily living (ADL) and motor complications, and levodopa-equivalent daily dose.

33 amination, -activities of daily living, and -motor complications, and Parkinson's disease Questionnai

34 Levodopa-induced motor complications are a common source of disability fo

35 Evidence suggests that motor complications are associated with non-physiologica

36 Experimental studies suggest that motor complications are due to non-physiological, interm

37 opment and maintenance of these drug-induced motor complications are not well understood.

38 Concerns about the development of motor complications arising from the early initiation of

39 activities of daily living, levodopa-induced motor complications (as assessed with the use of the Uni

40 advanced disease, has been characterized by motor complication, as well as by the potential emergenc

41 The motor complications associated with levodopa therapy, na

42 years) with advanced Parkinson's disease and motor complications at 26 centres in Germany, New Zealan

43 native initial therapy to delay the onset of motor complications but at the expense of more dopaminer

44 tion in Parkinson's disease with established motor complications, but rigorous studies, although expe

45 Dyskinesia, a motor complication caused by prolonged administration of

46 antiparkinson medications, time to onset of motor complications, change in nonmotor disability, and

47 However, its efficacy wanes over time as motor complications develop.

48 onset, and less asymmetry, levodopa-induced motor complications, dysautonomia, and dementia than tho

49 levodopa and younger patients had developed motor complications earlier, and patients who had starte

50 intment has been the development of aberrant motor complications following dopamine (DA) neuron graft

51 n; however, in animal studies, a decrease in motor complications has been reported in drug-naive anim

52 Once motor complications have developed, adjuvant therapy wit

53 o delay the onset and reduce the severity of motor complications in MPTP monkeys and PD patients.

54 mising approach to decreasing L-DOPA-induced motor complications in Parkinson's disease.

55 levodopa may be the price for a low rate of motor complications in patients with Parkinson's disease

56 are underway to address the hypothesis that motor complications in PD can be delayed if entacapone i

57 loss of putamen dopamine storage predisposes motor complications in PD, it cannot be the only factor

58 herapy is associated with the development of motor complications in the majority of Parkinson's disea

59 us dopamine release to examine, for example, motor complications in the treatment of PD.

60 With long-term use, levodopa causes motor complications including involuntary movements and

61 ing new therapeutic targets for limiting the motor complications induced by l-DOPA therapy.

62 avouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examina

63 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration o

64 r usual antiparkinsonian medication intake), motor complications (measured with the MDS-UPDRS IV), da

65 hermore, STN-DBS outcomes were favorable for motor complications (median difference in change scores

66 motor and nonmotor features (motor severity, motor complications, motor subtypes, quantitative motor

67 (l-DOPA)-induced dyskinesia (LID), a common motor complication of current pharmacotherapy of Parkins

68 Cognitive impairment is a common non-motor complication of Parkinson's disease (PD).

69 TN) deep brain stimulation (DBS) can improve motor complications of Parkinson's disease (PD) but may

70 pted treatment for patients experiencing the motor complications of Parkinson's disease (PD).

71 Cognitive and motor complications of Parkinson's disease were associat

72 ll aid the future treatment of motor and non-motor complications of Parkinson's disease.

73 functioning, while delaying or ameliorating motor complications of treatment, providing psychologica

74 -cell therapy-related cerebral edema, severe motor complications or late-onset neurotoxicity.

75 of daily living (P<0.001), levodopa-induced motor complications (P<0.001), and time with good mobili

76 also been used to study processes underlying motor complications, particularly dyskinesia, and for de

77 Besides motor complications, PD is also characterized by deficit

78 dication was associated with higher rates of motor complications, poor or moderate response was assoc

79 ciated with the development of motor and non-motor complications, primarily due to its fluctuating pl

80 Parkinson's disease (PD) patients with motor complications show a greater reduction in putamen

81 use of levodopa is commonly associated with motor complications such as dyskinesia, and both the dos

82 Non-motor complications, such as cognitive, psychiatric and

83 ges occurring in a rodent model of the human motor complication syndrome.

84 a produces many of the features of the human motor complication syndrome.

85 The most feared were the cognitive and motor complications termed AIDS dementia complex or HIV-

86 y people with Parkinson disease (PD) develop motor complications that are uncontrolled by levodopa do

87 gonists among people with PD who experienced motor complications that were uncontrolled by levodopa t

88 long-term utility of the drug is limited by motor complications, the development of features such as

89 However, motor complications uniquely related to levodopa treatme

90 luded activities of daily living (UPDRS-II), motor complications (UPDRS-IV), neuropsychological and s

91 ions to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 rati

92 luding disease progression and cognitive and motor complications, would be of significant clinical va